LenioBio is a Dusseldorf-based life science biotechnology company specializing in cell-free protein expression technology through their proprietary ALiCE (Almost Living Cell-Free Expression) platform. ALiCE is a plant-based, eukaryotic cell-free system that can produce complex proteins, including fully functional antibodies, within 24 hours. The system scales from early research to large-scale production. LenioBio offers ALiCE as a product and as a service (ALiCE as a Service) for custom protein expression. Funded by CEPI for vaccine production acceleration. Partnered with ReciBioPharm for vaccine candidate production and mAIbe for AI-driven antibody design. They are a technology/platform company, not a contract drug manufacturer.
Cell-free protein expression, ALiCE eukaryotic cell-free platform, rapid antibody production, vaccine antigen production, complex protein expression
1 site worldwide
No certifications on file yet.
No reviews available yet.
No documents available.